Business / Finance

RSS

Clinical Data reports $2.0 million revenue for third quarter 2011

Clinical Data, Inc. today announced operational and financial results for the third fiscal quarter ended December 31, 2010. The Company received approval from the U.S. Food and Drug Administration (FDA) of Viibryd™ for the treatment of adults with major depressive disorder (MDD) on January 21, 2011.

9 Feb 2011

Repligen third quarter total revenue increases 26% to $7,068,000

Repligen Corporation today reported results for the third quarter of fiscal year 2011, ended December 31, 2010. Total revenue for the quarter was $7,068,000 compared to total revenue of $5,617,000 for the third quarter of fiscal year 2010 ended December 31, 2009, an increase of $1,451,000 or 26%.

9 Feb 2011

A.P. Pharma provides update on response to APF530 Complete Response Letter

A.P. Pharma, Inc., a specialty pharmaceutical company, today provided an update on its progress toward responding to the Complete Response Letter for APF530 that the Company received from the U.S. Food and Drug Administration (FDA) in March 2010.

9 Feb 2011

MedRisk creates Risk Information and Business Intelligence unit

MedRisk, Inc., the workers' compensation industry leader in specialty managed care services, has announced the creation of its Risk Information and Business Intelligence (RIBI) unit. RIBI's first initiative is to roll out a new reporting platform featuring state-of-the-art graphics and outcomes analytics.

9 Feb 2011

Tibet Pharmaceuticals launches new corporate website

Tibet Pharmaceuticals, Inc., an emerging specialty pharmaceutical company engaged in the development, manufacturing and marketing of traditional Tibetan medicine in China, today announces the launch of a new corporate website.

9 Feb 2011

Eviagenics closes financing round for EUR 1.3 million to commercialize its technology platform

Eviagenics, a French biotech company, is pleased to announce the closing of a series A financing round to scale up its technical and commercial development. At this occasion the FCPR Emertec 4 managed by Emertec Management, CEA Investissement, and Genopole Premier Jour managed by CapDecisif Management provide a total contribution of EUR 1.3 million.

9 Feb 2011

Prestige Brands third quarter revenues increase 22.7% to $90.6 million

Prestige Brands Holdings, Inc. today announced results for the third quarter and nine months of fiscal year 2011, which ended on December 31, 2010. Following the close of the quarter, the Company completed the previously announced acquisition of the Dramamine® Brand in the U.S. from McNeil-PPC, Inc.

9 Feb 2011

Sartorius reports consolidated sales revenue of 659.3 million for fiscal 2010

Sartorius, a leading international laboratory and process equipment provider, successfully closed the year 2010. Sales revenue and earnings substantially surpassed the year-earlier figures. Financial guidance for the Group, which was raised during the course of 2010, was met and even exceeded for some targets.

From Sartorius 9 Feb 2011

DENTSPLY 2010 net sales increase 2.9% to record $2.221 billion

DENTSPLY International Inc. today announced sales and earnings for the three months and year ended December 31, 2010.

9 Feb 2011

Karo Bio fourth quarter net loss increases to MSEK 50.1

The January - December period and fourth quarter 2010 in brief

9 Feb 2011

Circassia acquires global rights to novel topical therapeutic for psoriasis and atopic dermatitis

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has acquired the worldwide development and commercialization rights to the novel topical therapeutic for psoriasis and atopic dermatitis, PAP-1. Circassia acquired the rights to the proprietary molecule from Airmid Inc, for an undisclosed upfront sum plus milestone payments and royalties on future product sales.

9 Feb 2011

Vitrolife fourth quarter sales increases 20% to SEK 81 million

A quarter with record sales concluded a year that set the stage for an increased potential in growth.

9 Feb 2011

Elan and Boehringer Ingelheim enter global collaboration for antibody-based therapeutics

Elan plc and Boehringer Ingelheim today announced that they have entered into a global technical development and manufacturing agreement for antibody-based therapeutics.

9 Feb 2011

Curaxis listed on Frankfurt Stock Exchange

Patrick S. Smith, President and Chief Executive Officer of Curaxis Pharmaceutical Corp., today announced Curaxis' new listing on the Frankfurt Stock Exchange (FSE). Curaxis was at the FSE for its opening on February 8, 2011, and will trade under the symbol 8CX:GR.

9 Feb 2011

Aushon BioSystems enters diagnostic development collaboration with Peking University Cancer Hospital

Aushon BioSystems, Inc., a leading provider of multiplex immunoassay products and services announced that it has signed a letter of intent to enter into a diagnostic development collaboration with Peking University Cancer Hospital ("PUCH"), Beijing, China.

9 Feb 2011

SwitchGear Genomics, BioCat enter distribution agreement for LightSwitch Luciferase Assay System in Europe

SwitchGear Genomics Inc., a leading provider of products for studying the regulatory elements in the human genome, today announced that the company signed an agreement for BioCat GmbH to distribute the innovative LightSwitch Luciferase Assay System™ in Europe.

9 Feb 2011

MRI Medical announces name change to Xeridiem Medical Devices

MRI Medical Inc. is changing its name to Xeridiem Medical Devices, Inc. as part of its corporate development plan.

9 Feb 2011

Kindred Healthcare signs definitive merger agreement to acquire RehabCare

Kindred Healthcare, and RehabCare Group, today jointly announced the signing of a definitive merger agreement under which Kindred will acquire RehabCare.

8 Feb 2011

Gizmox announces entry into Business Mobility Market

Gizmox, the developer of Visual WebGui Web & Cloud Platform, announced today their entrance into the Business Mobility Market. Visual WebGui's Instant CloudMove migration, which enables users to migrate client/server applications to the Web or Cloud, has now been extended to make business applications accessible from Mobile/Tablet devices using a simple mapping and configuration tool.

8 Feb 2011

ScinoPharm to be Clinical Data's sole API supplier of vilazodone hydrochloride during Viibryd's launch

ScinoPharm, a leading active pharmaceutical ingredient (API) and contract research and manufacturing (CRAM) service provider to the global pharmaceutical and biotechnology industry, will provide commercial manufacturing service of vilazodone hydrochloride active pharmaceutical ingredient (API) for Clinical Data, Inc.'s Viibryd™, a new drug entity recently approved by the United States Food and Drug Administration.

8 Feb 2011